SCHEMBL6937634

SCHEMBL6937634

CCC(C(=O)NN)c1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.59
POLB P06746 1/20 0.59
CTSD P07339 1/20 0.58
KCNQ2 O43526 3/20 0.58
CRHBP P24387 2/20 0.58
CRHR2 Q13324 2/20 0.58
LMNA P02545 1/20 0.58
HTT P42858 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
KDM4A O75164 1/20 0.56
MAPT P10636 1/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
GAA P10253 1/20 0.55
HDAC3 O15379 3/20 0.54
HDAC4 P56524 3/20 0.54
HDAC1 Q13547 3/20 0.54
HDAC7 Q8WUI4 3/20 0.54
HDAC2 Q92769 3/20 0.54
HDAC10 Q969S8 3/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL1051954 0.87 ALDH1A1 (0.48) ALDH1A1POLBCTSDKCNQ2CRHBP
SCHEMBL960701 0.86 CRHBP (0.49) ALDH1A1POLBCTSDKCNQ2CRHBP
SCHEMBL15348451 0.86 CRHBP (0.49) ALDH1A1POLBCTSDKCNQ2CRHBP
SCHEMBL8113733 0.86 CTSD (0.55) ALDH1A1POLBCTSDKCNQ2CRHBP
SCHEMBL2049579 0.83 ALDH1A1 (0.66) ALDH1A1POLBKCNQ2CRHBPCRHR2
SCHEMBL2842510 0.83 HDAC3 (0.63) ALDH1A1POLBKCNQ2CRHBPCRHR2
SCHEMBL29873777 0.83 CTSD (0.60) CTSDKCNQ2MAPTHDAC3HDAC4
SCHEMBL25323509 0.82 KCNQ2 (0.50) ALDH1A1POLBKCNQ2CRHBPCRHR2
SCHEMBL13527493 0.82 ALDH1A1 (0.56) ALDH1A1POLBKCNQ2CRHBPCRHR2
SCHEMBL4519669 0.82 FFAR2 (0.55) ALDH1A1POLBKCNQ2CRHBPCRHR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP claimed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO claimed
EP-1272456-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS Abbott Laboratories (US) 2003-01-08 EP disclosed
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors ABBOTT LABORATORIES 2002-01-03 US disclosed
WO-2001079157-A1 HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS ABBOTT LABORATORIES (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002152-A1 Hydrazide and alkoxyamide angiogenesis inhibitors METAP2, METAP1, ANPEP ALDH1A1 583/4885POLB 1563/4885CTSD 1567/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.